Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.72
Bid: 3.20
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.64 (20.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.72
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Technology Update

6 Jun 2017 07:00

RNS Number : 2009H
Plant Health Care PLC
06 June 2017
 

6 June 2017

Plant Health Care plc(the "Company" ", "PHC" or "Plant Health Care")New Technology Update

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to its New Technology business.

Highlights

- Evaluation of Innatus 3G continues to expand. The four major industry partners have increased the scale of their 2017 trials. Three other companies have signed evaluation agreements and are conducting field trials.

- A total of eight agreements have also now been signed concerning T-Rex 3G and Y-Max-3G.

- Strong progress continues within Plant Health Care on its capability to make, formulate and register PREtec peptides.

- The Company remains on track to deliver a revenue-generating licence by the end of 2017 and the first competitive licensing process in early 2018.

 

Innatus 3G

Four of the top six agrochemicals companies have been evaluating Innatus 3G since 2015. They are focused on three core agricultural benefits - yield increase, disease and nematode protection and drought resistance - mainly in the largest commercial crops corn (maize) and soybean. Building on their 2016 results, all are running trials of lead peptides from this platform in 2017.

By early 2017, three other companies had signed agreements to evaluate Innatus 3G. Their field trials, in other smaller crops, are underway in Europe and South America.

In recent weeks several partners have approached PHC with plans to expand their 2017 trials further. Of particular interest is the control of Asian Soybean Rust, a fungal disease which is a major threat to the soybean crop in Brazil. This disease has developed resistance to most conventional fungicides. Innatus 3G peptides work very differently, and when sprayed in mixtures with standard fungicides, they have shown significantly improved disease control in PHC's trials. This has the potential to increase the effectiveness and extend the commercial life of those established products.

T-Rex 3G and Y-Max 3G

PHC's new technology platforms, T-Rex 3G and Y-Max 3G, were first presented to the industry in 2016. T-Rex 3G is a class of signal peptides optimised for nematode suppression, while Y-Max 3G peptides are biostimulants which increase yield.

A total of eight companies have so far signed up to evaluate one or both of these new platforms, including the majors who are evaluating Innatus 3G. Trials are in progress in three continents in a range of crops, with two lead peptides from each of T-Rex 3G and Y-Max 3G. The majors are focused mainly on corn and soybean, while others are working on a wider range of crops.

The Company continues to aim to secure the first revenue-generating licence of one of its PREtec technologies in 2017.

PHC's product development capability

Plant Health Care has increased its product development activity. This includes substantially expanding its own 2017 field trials and contract testing programme. But because partners' evaluations of PREtec peptides are on a much larger scale than in 2016, collectively they are spending many times more than the Company is.

Plant Health Care's work on the physical stability of peptides in formulations and their compatibility with agrochemicals continues to show promising results. We expect the most cost-effective means of peptide manufacture to be by fermentation, and laboratory scale production trials are on track. The first lead peptides produced by fermentation are being evaluated and will shortly be entering field trials.

 

Chris Richards, Executive Chairman & Interim CEO, said "Momentum continues to build. As we approach the expected 2018 date for licensing of first rights to Innatus 3G, partners are stepping up their evaluations. Our lead peptides from each platform are performing well in independent trials, carried out by our partners."

"It is a great vote of confidence in our proprietary technology. Every one of our initial partners is now testing one or both of T-Rex 3G and Y-Max 3G, alongside Innatus 3G. Our new partners are expanding the range of crops to which our products can bring benefits. This year, partners will spend much more than us on evaluating our proprietary technology."

"We are well positioned for the first licensing of our PREtec technology by the end of 2017, with competitive licensing of Innatus 3G to start in early 2018."

 

Enquiries:

Plant Health Care plc

Dr Chris Richards, Executive Chairman and Interim CEO

Tel: +44 (0) 18 3788 0083

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke

Tel: +44 (0) 20 3100 2000

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESUGUWCQUPMGMA
Date   Source Headline
30th Oct 20147:00 amRNSPHC & Sipcam Enter Agreement
27th Oct 20147:00 amRNS3G Peptide Technology Platform shows major promise
23rd Oct 20144:29 pmRNSHolding(s) in Company
6th Oct 201411:25 amRNSDirector/PDMR Shareholding
2nd Oct 20147:00 amRNSDirector/PDMR Shareholding
15th Sep 20147:00 amRNSHalf Yearly Report
19th Aug 201410:28 amRNSAIM Blocklisting Return
12th Aug 20143:10 pmRNSTR-1 Notification of Major Interest in Shares
22nd Jul 20144:10 pmRNSTR-1 Notification of Major Interest in Shares
30th Jun 20149:18 amRNSTotal Voting Rights
5th Jun 201412:45 pmRNSTR-1 Notification of Major Interest in Shares
22nd May 20147:00 amRNSDelisting of shares from the CISX
8th May 20141:30 pmRNSAGM Voting Results
15th Apr 201411:30 amRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSDirector/PDMR Shareholding
9th Apr 20142:15 pmRNSDirector's Dealing - Grant of Share Options
9th Apr 20142:00 pmRNSTR-1 Notification of Major Interest in Shares
7th Apr 20145:15 pmRNSPublication of Annual Report 2013 & Notice of AGM
31st Mar 20143:45 pmRNSTotal Voting Rights
24th Mar 20147:00 amRNSPreliminary Results
3rd Mar 20144:35 pmRNSPrice Monitoring Extension
28th Feb 20141:00 pmRNSTotal Voting Rights
19th Feb 201412:15 pmRNSBlocklisting Interim Review
17th Feb 20149:45 amRNSTR-1 Notification of Major Interest in Shares
6th Feb 20144:40 pmRNSSecond Price Monitoring Extn
6th Feb 20144:35 pmRNSPrice Monitoring Extension
31st Jan 20143:00 pmRNSTotal Voting Rights
15th Jan 20147:00 amRNSTrading Statement
29th Nov 201312:12 pmRNSDirector's Shareholding
25th Nov 20133:15 pmRNSDivestment of non-core subsidiary
18th Oct 20135:00 pmRNSTR-1 Notification of Major Interest in Shares
30th Sep 20135:00 pmRNSTotal Voting Rights
23rd Sep 201310:30 amRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSAppointment of Adviser
18th Sep 20133:15 pmRNSDirector/PDMR Shareholding
16th Sep 20137:03 amRNSDirectorate Change
16th Sep 20137:00 amRNSHalf Yearly Report
19th Aug 20132:30 pmRNSBlocklisting Interim Review
30th Jul 20137:01 amRNSUpdate on Harpin
30th Jul 20137:00 amRNSPHC announces plans for Harpin seed treatment
22nd Jul 201311:00 amRNSPHC hires Glen Donald as VP Business Development
19th Jul 20137:00 amRNSHead Office Relocation,Research Facility Expansion
15th Jul 20135:15 pmRNSDirector/PDMR Shareholding
5th Jul 20137:00 amRNSUpdate on CISX Listing
3rd Jul 20137:00 amRNSNew Long-Term Incentive Plan and Grant of Awards
7th Jun 20134:15 pmRNSDirectorate Change
31st May 201311:30 amRNSTotal Voting Rights
21st May 201312:00 pmRNSHarpin Granted Federal Registration in Mexico
10th May 20134:45 pmRNSDirector/PDMR Shareholding
9th May 20131:20 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.